Neuren FDA meeting confirms Phase 3 plan for Rett syndrome
Filed with ASX · · 1 page · English
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- Presentations and publication for Rett syndrome trials
- Change of Director's Interest Notice
- Notice under section 708A(5)(e) of the Corporations Act
- Results of Meeting
- Neuren Pharmaceuticals reports 2017 half-year results
Later from Neuren Pharmaceuticals
- Consolidation/Split - NEU
- Neuren announces new US patent to be granted for NNZ-2591
- Preliminary Final Report
- S&P DJ Indices Announces March Quarterly Rebalance
- Disclosure under Listing Rule 4.3D
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals